Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report released on Monday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $2.47 on Monday. The firm’s fifty day moving average price is $2.36 and its 200 day moving average price is $2.38. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67. The firm has a market cap of $99.36 million, a price-to-earnings ratio of 22.41 and a beta of 1.77.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. boosted its position in shares of Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Oramed Pharmaceuticals during the 1st quarter worth $68,000. Finally, Renaissance Technologies LLC boosted its position in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.